Abstract
We have introduced three Hirschsprung (HSCR) mutations localized in the tyrosine kinase domain of RET into the RET/PTC2 chimaeric oncogene which is capable of transforming NIH3T3 mouse fibroblasts and of differentiating pC12 rat pheochromocytoma cells. The three HSCR mutations abolished the biological activity of RET/PTC2 in both cell types and significantly decreased its tyrosine phosphorylation. By contrast, a rare polymorphism in exon 18 does not alter the transforming capability of RET/PTC2 or its tyrosine phosphorylation. These data suggest a loss of function effect of HSCR mutations which might act through a dominant negative mechanism. Our model system is therefore capable of discriminating between causative HSCR mutations and rare polymorphisms in the tyrosine kinase domain of RET.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Takahashi, M., Ritz, J. & Cooper, G.M. Activation of a novel human transforming gene, RET, by DMA rearrangement. Cell 42, 581–588 (1985).
Takahashi, M., Buma, Y., Iwamoto, T., Inaguma, Y., Ikeda, H. & Hiai, H. Cloning and expression of the RET proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3, 571–578 (1988).
Takahashi, M., Buma, Y. & Hiai, H. Isolation of RET proto-oncogene cDNA with an amino-terminal signal sequence. Oncogene 4, 805–806 (1989).
Ceccherini, I. et al. Exon structure and flanking intronic sequences of the human RET proto-oncogene. Biochem. Biophys. Res. Comm. 196, 1288–1295 (1993).
Pachnis, V., Mankoo, B. & Costantini, F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 119, 1005–1017 (1993).
Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F. & Pachnis, V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor ret. Nature 367, 380–383 (1994).
Mulligan, L.M. et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363, 458–460 (1993).
Donis-Keller, H. et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. molec. Genet. 2, 851–856 (1993).
Mulligan, L.M. et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet. 6, 70–74 (1994).
Hofstra, R.M.W. et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367, 375–376 (1994).
Carlson, K.M. et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc. natn. Acad. Sci. U.S.A. 91, 1579–1583 (1994).
Eng, C. et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum. molec. Genet 3, 237–241 (1994).
Romeo, G. et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 367, 377–378 (1994).
Edery, P. et al. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 367, 378–380 (1994).
Luo, Y. et al. Heterogeneity and low detection rate of RET mutations in Hirschsprung disease. Eur. J. hum. Genet. 2, 272–280 (1994).
Hanks, S.K., Quinn, A.M. & Hunter, T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241, 42–52 (1988).
Fusco, A. et al. A new oncogene in human papillary thyroid carcinomas and their lymphonodal metastases. Nature 328, 170–172 (1987).
Grieco, M. et al. PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human papillary thyroid carcinomas. Cell 60, 557–563 (1990).
Pierotti, M.A. et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D1OS170 and RET and creating the oncogenic sequence RET/PTC. Proc. nafn. Acad. Sci. U.S.A. 89, 1616–1620 (1992).
Bongarzone, I. et al. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of RET tyrosine kinase and the regulatory subunit RIα of cyclic AMP-dependent protein kinase A. molec. cell. Biol. 13, 358–366 (1993).
Sozzi, G. et al. A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. Genes Chrom. Cancer 9, 244–250 (1994).
Bongarzone, I. et al. Frequent activation of RET proto-oncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res. 54, 2979–2985 (1994).
Santoro, M. et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 9, 509–516 (1994).
Minoletti, F. et al. The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2. Genes Chrom. Cancer 11, 51–57 (1994).
Zickj, S.K. & Taylor, S.S. Interchian disulfide bonding in the regulatory subunit of cAMP-dependent protein kinase I*. J. biol. Chem. 257, 2287–2293 (1982).
Greco, A. et al. Expression of TRK-T1 oncogene induces differentiation of PC12 cells. Cell Growth Differentiation 4, 539–546 (1993).
Van Heyningen, V. One gene – four syndromes. Nature 367, 319–320 (1994).
Santoro, M. et al. Germ-line mutations of MEN 2A and MEN 2B activate RET as a dominant transforming gene by different molecular mechanisms. Science 267, 381–383 (1995).
Songyang, Z. et al. Catalytic specificity of protein tyrosine kinases is critical for selective signalling. Nature 373, 536–539 (1995).
Mulligan, L.M. et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum. molec. Genet. 3, 2163–2167 (1994).
Fantl, W.J., Johnson, D.E. & Williams, L.T. Signalling by receptor tyrosine kinases. A. Rev. Biochem. 62, 453–481 (1993).
Longati, P., Bardelli, A., Ponzetto, C., Naldini, L. & Comoglio, P.M. Tyrosine 1234–1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 9, 49–57 (1994).
Takahashi, M., Asai, N., Iwashita, T., Isomura, T., Miyazaki, K. & Mutsushi, M. Characterization of the RET proto-oncogene product expressed in mouse L cells. Oncogene 8, 2925–2929 (1993).
Ohmichi, M., Decker, S.J., Pang, L. & Saltiel, A.R., Phospholipase C-γl directly associates with the p70 TRK oncogene product through its SRC homology domains. J. biol. Chem. 266, 14858–14861 (1991).
Obermeier, A., Halfter, H., Wiesmuller, K.H., Jung, G., Schlessinger, J. & Ullrich, A. Tyrosine 785 is a major determinant of Trk-substrate interaction. EMBO J. 12, 933–941 (1993).
Borrello, M.G. et al. The oncogenic versions of the RET and TRK tyrosine kinases bind She and Grb2 adaptor proteins. Oncogene 9, 1661–1668 (1994).
Zhen, Z., Giordano, S., Longati, P., Medico, E., Campiglio, M. & Comoglio, P.M. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met). Oncogene 9, 1691–1697 (1994).
Hubbard, S.R., Wei, L., Ellis, L. & Hendrickson, W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 746–754 (1994).
Rodrigues, G.A. & Park, M. Oncogenic activation of tyrosine kinases. Curr.Opin. Genet. Devel. 4, 15–24 (1994).
Wigler, M., Silverstein, S., Lee, L.S., Pellicer, A., Cheng, Y. & Axel, R. Transfer of purified herpes virus thymidina kinase gene to cultured mouse cells. Cell 11, 223–232 (1977).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pasini, B., Borrello, M., Greco, A. et al. Loss of function effect of RET mutations causing Hirschsprung disease. Nat Genet 10, 35–40 (1995). https://doi.org/10.1038/ng0595-35
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ng0595-35
This article is cited by
-
ERNICA guidelines for the management of rectosigmoid Hirschsprung’s disease
Orphanet Journal of Rare Diseases (2020)
-
Defining the transcriptomic landscape of the developing enteric nervous system and its cellular environment
BMC Genomics (2017)
-
RET and EDNRB mutation screening in patients with Hirschsprung disease: Functional studies and its implications for genetic counseling
European Journal of Human Genetics (2016)
-
PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy
Endocrine (2015)
-
RET is a potential tumor suppressor gene in colorectal cancer
Oncogene (2013)